Engineered immune cells take on tough lymphoma in new trial
NCT ID NCT04531046
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing a personalized cell therapy called axi-cel for people with aggressive B-cell lymphoma that has come back or not responded to treatment, and who cannot undergo a stem cell transplant. The therapy uses the patient's own immune cells, which are modified in a lab to better attack cancer cells. The main goal is to see how many patients achieve a complete response, meaning no signs of cancer remain.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
axicabtagene ciloleucel (axi-cel), a CAR T-cell therapy made from the patient's own immune cells
What this could lead to
If successful, this could offer a powerful treatment option for people with aggressive B-cell lymphoma who cannot have a stem cell transplant.
What could go wrong
This is a mid-stage trial with only 62 participants, so results may not apply to everyone. CAR T-cell therapy can cause serious side effects like cytokine release syndrome and neurological problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
APHP - Hôpital Henri Mondor
Créteil, France
-
APHP - Hôpital Saint Louis
Paris, 75475, France
-
CH Liège
Liège, 4000, Belgium
-
CHU Brabois
Vandœuvre-lès-Nancy, 54511, France
-
CHU Clermont Ferrand - Hôpital Estaing
Clermont-Ferrand, France
-
CHU de Bordeaux - Hôpital Haut Lévêque
Bordeaux, France
-
CHU de Dijon - Hôpital le Bocage
Dijon, 21000, France
-
CHU de Nantes - Hôtel Dieu
Nantes, 44093, France
-
CHU de Rennes - Hôpital de Pontchaillou
Rennes, 35003, France
-
Centre Hospitalier Lyon Sud
Pierre-Bénite, 69495, France
-
Hopital La Pitié Salpétriere
Paris, France
-
Hôpital Claude Huriez
Lille, 59037, France
-
Hôpital Saint Antoine
Paris, France
-
Hôpital Saint Eloi
Montpellier, 34295, France
-
IUCT Oncopole
Toulouse, France
-
Institut de Cancérologie Gustave Roussy
Villejuif, France